FMC7 antigen expression on normal and malignant B-cells can be predicted by expression of CD20

被引:0
作者
Hübl, W
Iturraspe, J
Braylan, RC
机构
[1] Univ Florida, Coll Med, Dept Pathol, Gainesville, FL 32610 USA
[2] Univ Florida, Shands Hosp, Gainesville, FL USA
来源
CYTOMETRY | 1998年 / 34卷 / 02期
关键词
flow cytometry; lymphomas; chronic lymphoid leukemias; FMC7; CD20;
D O I
10.1002/(SICI)1097-0320(19980415)34:2<71::AID-CYTO2>3.0.CO;2-F
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Most antibody panels proposed for flow cytometric immunophenotyping of non-Hodgkin's lymphomas and chronic lymphoid leukemias include anti-CD20 and FMC7 antibodies. As in our experience, reactivity of B-cells with these antibodies seemed to be correlated, we evaluated whether the simultaneous use of anti-CD20 and FMC7 antibodies is justified. Using flow cytometry, we measured the binding of these 2 antibodies to the B-ce(ls of 67 bone marrow aspirates, 31 lymph node biopsies, 18 peripheral blood specimens, and 12 tissue samples from other locations. The diagnoses included 50 cases without overt abnormalities, 5 reactive lymphadenopathies, 56 lymphomas and chronic lymphoid neoplasias, and 17 cases with other malignancies. Although CD20 expression was consistently higher, we observed a significant and strong correlation between CD20 and FMC7 antigen expression on B-lymphocytes, irrespective of the nature of the sample or disease (r = 0.910; P < 0.001). Moreover, FMC7 antigen expression on B-cells could he predicted by CD20 expression with a sensitivity of 96%, a specificity of 94% and an efficiency of 96%. Our results show that although differing in intensity, expression of CD20 on B-cells closely parallels that of FMC7 antigen. We, therefore, conclude that little additional information is revealed by using FMC7 in immunophenotyping of non-Hodgkin's lymphomas or chronic lymphoid leukemias if intensity of CD20 expression is taken into consideration. (C) 1998 Wiley-Liss, Inc.
引用
收藏
页码:71 / 74
页数:4
相关论文
共 21 条
[1]   REDUCED EXPRESSION OF CD20 ANTIGEN AS A CHARACTERISTIC MARKER FOR CHRONIC LYMPHOCYTIC-LEUKEMIA [J].
ALMASRI, NM ;
DUQUE, RE ;
ITURRASPE, J ;
EVERETT, E ;
BRAYLAN, RC .
AMERICAN JOURNAL OF HEMATOLOGY, 1992, 40 (04) :259-263
[2]   PROPOSALS FOR THE CLASSIFICATION OF CHRONIC (MATURE) B-LYMPHOID AND T-LYMPHOID LEUKEMIAS [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
JOURNAL OF CLINICAL PATHOLOGY, 1989, 42 (06) :567-584
[3]  
Borowitz MJ, 1997, CYTOMETRY, V30, P236, DOI 10.1002/(SICI)1097-0320(19971015)30:5<236::AID-CYTO4>3.0.CO
[4]  
2-F
[5]  
Braylan R C, 1988, Cytometry Suppl, V3, P73
[6]  
BRAYLAN RC, 1989, ARCH PATHOL LAB MED, V113, P627
[7]   ANALYSIS OF LYMPHOMAS BY FLOW-CYTOMETRY - CURRENT AND EMERGING STRATEGIES [J].
BRAYLAN, RC ;
BENSON, NA ;
ITURRASPE, J .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1993, 677 :364-378
[8]  
Braylan RC, 1997, CYTOMETRY, V30, P245
[9]  
CATOVSKY D, 1981, BLOOD, V58, P406
[10]   DETECTION OF SUBGROUPS OF CHRONIC B-CELL LEUKEMIAS BY FMC7 MONOCLONAL-ANTIBODY [J].
HUH, YO ;
PUGH, WC ;
KANTARJIAN, HM ;
STASS, SA ;
CORK, A ;
TRUJILLO, JM ;
KEATING, MJ .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1994, 101 (03) :283-289